Status: Recruiting
Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC
This is a multicenter, two-arm randomized, parallel group design trial to evaluate superiority and safety of low dose Nivolumab (40mg) combined with standard chemotherapy versus standard chemotherapy alone in patients with non-small cell lung cancer.
Participants needed: 123
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Dr Arvindran A/L AlagaUpdated: Jul 3, 2025Locations: 1
Eligibility criteria
Male/female participants who are at least 18 years of age on the day of signing... [+10]
Presence of EGFR, ALK , ROS1 mutation(s). [+11]